Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge
Source: SeekingAlpha
2026-02-04 07:55:40 ET
Amgen ( AMGN ) reported strong Q4 2025 results and provided full-year 2026 guidance that was above Street expectations. The company is managing losses of exclusivity on several large products quite well and it expects to deliver top and bottom-line growth in 2026 despite recent launches of biosimilar/generic versions of Prolia, Xgeva, and Ravicti. This is no small feat as these products generated approximately $7 billion in combined net sales last year....
Read the full article on Seeking Alpha
For further details see:
Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge
Viridian Therapeutics Inc Com
NASDAQ: VRDN
VRDN Trading
-1.29% G/L:
$27.445 Last:
286,450 Volume:
$27.69 Open:
VRDN Latest News
February 26, 2026 07:01:00 am
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
VRDN Stock Data
$2,867,173,362
93,934,024
4.1%
67
N/A
Biotechnology & Life Sciences
Healthcare
US
Waltham
